ストックスクリーナーアプリを入手
2.17
3.77%
-0.085
前日終値:
$2.255
開ける：
$2.35
24時間の取引高:
4.87M
Relative Volume:
1.00
時価総額：
$454.99M
収益：
$95,000
当期純損益:
$-327.27M
株価収益率:
-1.0236
EPS:
-2.12
ネットキャッシュフロー:
$-239.25M
1週間 パフォーマンス:
+6.37%
1か月 パフォーマンス:
+17.93%
6か月 パフォーマンス:
-20.80%
1年 パフォーマンス:
-51.13%
1日の値動き範囲:
$2.14
$2.39
1週間の範囲:
$2.14
$3.78
52週間の値動き範囲:
$1.32
$5.775
Allogene Therapeutics Inc Stock (ALLO) Company Profile
名前
Allogene Therapeutics Inc
セクター
電話
(650) 457-2700
住所
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
ALLO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.17 | 454.99M | 95,000 | -327.27M | -239.25M | -2.12 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-08-08 | 再開されました | Oppenheimer | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Overweight |
| 2024-01-05 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-01-05 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-06-26 | 再開されました | Oppenheimer | Outperform |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-01-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-06 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | ダウングレード | BofA Securities | Buy → Underperform |
| 2022-08-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | アップグレード | Goldman | Neutral → Buy |
| 2022-06-03 | 開始されました | Robert W. Baird | Neutral |
| 2022-02-28 | 繰り返されました | B. Riley Securities | Buy |
| 2021-10-20 | 開始されました | Cowen | Outperform |
| 2021-10-08 | ダウングレード | Goldman | Buy → Neutral |
| 2021-10-08 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-23 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | 再開されました | Jefferies | Buy |
| 2021-05-20 | アップグレード | Truist | Hold → Buy |
| 2021-05-14 | 開始されました | B. Riley Securities | Buy |
| 2021-01-26 | アップグレード | Stifel | Hold → Buy |
| 2020-12-10 | 再開されました | H.C. Wainwright | Buy |
| 2020-11-24 | 開始されました | BofA Securities | Buy |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Outperform |
| 2020-06-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-19 | アップグレード | ROTH Capital | Neutral → Buy |
| 2020-05-15 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-05-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-14 | ダウングレード | SunTrust | Buy → Hold |
| 2020-04-13 | 開始されました | SunTrust | Buy |
| 2020-03-13 | 開始されました | H.C. Wainwright | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-24 | 開始されました | Berenberg | Hold |
| 2019-12-18 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-11-04 | 開始されました | Canaccord Genuity | Buy |
| 2019-08-09 | 開始されました | BTIG Research | Buy |
| 2019-06-05 | 開始されました | ROTH Capital | Neutral |
| 2019-05-31 | 開始されました | Guggenheim | Neutral |
| 2019-05-23 | 開始されました | Stifel | Hold |
| 2019-03-29 | 開始されました | Piper Jaffray | Overweight |
すべてを表示
Allogene Therapeutics Inc (ALLO) 最新ニュース
Insider Sell: Deborah Messemer Sells Shares of Allogene Therapeu - GuruFocus.com
Allogene therapeutics director Deborah Messemer sells $32,350 in stock - Investing.com
Allogene Therapeutics Director Sells Shares Under Trading Plan - TradingView
Watsco Posts Upbeat Results, Joins GeneDx, Intel And Other Big Stocks Moving Higher On Tuesday - Benzinga
Baird ‘encouraged’ by Allogene CAR-T therapy update - TipRanks
Allogene Therapeutics' SWOT analysis: CAR T pioneer's stock faces pivotal year - MSN
Diffuse Large B-cell Lymphoma Market Expected to rise, 2034 | - openPR
Allogene stock hits 52-week low at $1.76 amid market challenges - Investing.com Nigeria
Allogene leaps on allogeneic CAR-T therapy success - The Pharma Letter
Allogene reports promising results for CAR T therapy in lymphoma - MSN
abrdn plc Invests $776,000 in Allogene Therapeutics, Inc. (NASDAQ:ALLO) - MarketBeat
Allogene stock plunges to 52-week low at $1.33 amid steep annual decline - Investing.com Nigeria
Allogene Therapeutics Announces Publication of Durable - GlobeNewswire
Allogene reports promising results for CAR T therapy in lymphoma By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Positive Phase 1 Results for Cema-Cel in Treating Relapsed/Refractory Large B-Cell Lymphoma - Nasdaq
Allogene stock plunges to 52-week low at $1.33 amid steep annual decline By Investing.com - Investing.com South Africa
A stock that deserves closer examination: Allogene Therapeutics Inc (ALLO) - US Post News
Ratio Revelations: Allogene Therapeutics Inc (ALLO)’s Financial Metrics in the Spotlight - The Dwinnex
Earl Martin Douglas Sells 6,404 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Insider Sells $25,215.66 in Stock - MarketBeat
Allogene Therapeutics Falls To US$1.51, But Insiders Sold At Lower Price - Simply Wall St
FDA Clears Allogene's IND for CAR T Therapy in Autoimmune Diseases - MSN
Allogene Therapeutics Executives Sell Shares to Cover Tax Obligations - TradingView
Follicular Lymphoma Pipeline 2024: Comprehensive Clinical - openPR
Allogene Therapeutics Announces Participation in February Investor Conferences - GlobeNewswire
Allogene Therapeutics Joins Elite Biotech Lineup at Major Oppenheimer Conference - StockTitan
Allogene Therapeutics executive to depart, consulting agreement planned - MSN
Allogene's Dual-Acting CAR T Candidate ALLO-329 Gets FDA Green Light for Autoimmune Disease Trial - CRISPR Medicine News
Allogene Therapeutics, Inc. Announces Departure of Timothy MooreOn January 23, 2025, Allogene Therapeutics, Inc. (NASDAQ: ALLO) revealed in an 8-K filing that Timothy Moore, the Company’s incumbent executive, would be concluding his tenure with the - Defense World
Allogene Therapeutics Activates First Clinical Sites for Pivotal Phase 2 Trial of Cema-Cel - CRISPR Medicine News
Cell Therapy Weekly: Phase I Trial for Autoimmune CAR-T Therapy - RegMedNet
Allogene Therapeutics executive to depart, consulting agreement planned By Investing.com - Investing.com South Africa
Allogene Therapeutics Announces Benjamin M. Beneski as Senior Vice President and Chief Technical Officer - BioSpace
Allogene Therapeutics Announces Executive Departure and Transition - TipRanks
Allogene’s ALLO-329 gains IND clearance for autoimmune diseases - BioWorld Online
Allogene Therapeutics Inc (ALLO) 財務データ
収益
当期純利益
現金流量
EPS
0.27%
3.05%
大文字化:
|
ボリューム (24 時間):